Insulin Resistance in Patients Undergoing Peritoneal Dialysis: Can We Improve It?

Phosphate depletion in insulin-insensitive skeletal muscle drives AMPD activation and sarcopenia in chronic kidney disease

“…Insulin resistance is a common finding in patients with CKD, particularly in those requiring dialysis 43 , 44 , 45 , 46 including in non-diabetic patients. 47 , 48 Even though circulating glucose levels in 14-h fasting mice undergoing CKD-dependent sarcopenia or sham operation did not differ (116.2 ± 14.7 mg/dL in mice with sarcopenia versus 107.7 ± 18.7 mg/dL in sham), insulin levels following an oral glucose exposure were significantly higher in wild type mice with sarcopenia ( Figures 2 A and 2B, black symbols).…”

Improvement of clinical outcomes in patients undergoing peritoneal dialysis using hydroxymethylglutaryl-CoA reductase inhibitors: A systematic review and meta-analysis

“…independently assessed the 24 relevant studies included. 6,8,9,12,13,[23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] After excluding seven studies without full-text articles, [33][34][35][36]39 17 studies were left. Subsequently, we critically appraised all 17 studies, and their inclusion was independently analyzed by two review authors (D.Y.L.…”

“…1. Among the remaining 9 studies for qualitative synthesis, six reported secondary outcomes, 12,13,[23][24][25][26] and seven reported primary outcomes, including all-cause mortality or CVD. However, two studies had mixed HD and PD patients without further PD subgroup analysis, 30,31 and one study's endpoint was a composite of all-cause mortality, nonlethal acute myocardial infarction, coronary artery bypass graft surgery, and percutaneous transluminal coronary angioplasty.…”

“…13,23 An unclear blinding design was reported in three RCTs. 24–26 All analyses were performed on an intention-to-treat (ITT) basis, except for two studies that did not mention whether they were based on the ITT population. 12,25 Supplemental Figure 2, http://links.lww.com/JCMA/A165 shows the risk of bias assessed using the Cochrane risk of bias tool for RCTs.…”